Citadel Advisors
ORGS

Citadel Advisors’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Citadel Advisors’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-250
Closed -$4.88K – 15713
2022
Q4 		$4.88K Buy
+250
New +$4.26K ﹤0.01% 14058
2022
Q2 		– Sell
-1,050
Closed -$36K – 14381
2022
Q1 		$36K Sell
1,050
-1,550
-60% -$47.1K ﹤0.01% 13007
2021
Q4 		$75K Sell
2,600
-320
-11% -$12.5K ﹤0.01% 12991
2021
Q3 		$145K Buy
2,920
+310
+12% +$15.6K ﹤0.01% 12421
2021
Q2 		$132K Buy
+2,610
New +$131K ﹤0.01% 12649

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Citadel Advisors's ORGS Position: Q1 2023 in Review

Citadel Advisors sold out of Orgenesis Inc. Common Stock (ORGS) in Q1 2023, closing a stake of 1,532 shares — an estimated $29.9K sold.

Citadel Advisors first reported a position in ORGS in Q1 2021 and held it in 5 quarters. The position peaked at $143K in Q2 2021. 20 funds tracked by Wall St. Rank hold ORGS as of Q1 2023.

  • Citadel Advisors reported no remaining Orgenesis Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 1,532 Orgenesis Inc. Common Stock shares in Q1 2023, an estimated $29.9K.
  • Citadel Advisors first reported a position in Orgenesis Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Citadel Advisors's Orgenesis Inc. Common Stock position peaked at $143K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.